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Abstract
Background
Tuberculosis is an important risk factor for chronic respiratory disease in resource poor set-
tings. The persistence of abnormal spirometry and symptoms after treatment are well
described, but the structural abnormalities underlying these changes remain poorly defined,
limiting our ability to phenotype post-TB lung disease in to meaningful categories for clinical
management, prognostication, and ongoing research. The relationship between post-TB
lung damage and patient-centred outcomes including functional impairment, respiratory
symptoms, and health related quality of life also remains unclear.
Methods
We performed a systematic literature review to determine the prevalence and pattern of
imaging-defined lung pathology in adults after medical treatment for pleural, miliary, or pul-
monary TB disease. Data were collected on study characteristics, and the modality, timing,
and findings of thoracic imaging. The proportion of studies relating imaging findings to spi-
rometry results and patient morbidity was recorded. Study quality was assessed using a
modified Newcastle-Ottowa score. (Prospero Registration number CRD42015027958)
Results
We identified 37 eligible studies. The principle features seen on CXR were cavitation (8.3–
83.7%), bronchiectasis (4.3–11.2%), and fibrosis (25.0–70.4%), but prevalence was highly
variable. CT imaging identified a wider range of residual abnormalities than CXR, including
nodules (25.0–55.8%), consolidation (3.7–19.2%), and emphysema (15.0–45.0%). The
prevalence of cavitation was generally lower (7.4–34.6%) and bronchiectasis higher (35.0–
86.0%) on CT vs. CXR imaging. A paucity of prospective data, and data from HIV-infected
adults and sub-Saharan Africa (sSA) was noted. Few studies related structural damage to
physiological impairment, respiratory symptoms, or patient morbidity.
PLOS ONE | DOI:10.1371/journal.pone.0161176 August 12, 2016 1 / 17
a11111
OPEN ACCESS
Citation: Meghji J, Simpson H, Squire SB, Mortimer
K (2016) A Systematic Review of the Prevalence and
Pattern of Imaging Defined Post-TB Lung Disease.
PLoS ONE 11(8): e0161176. doi:10.1371/journal.
pone.0161176
Editor: Philip C Hill, University of Otago, NEW
ZEALAND
Received: February 26, 2016
Accepted: August 1, 2016
Published: August 12, 2016
Copyright: © 2016 Meghji et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: Data for this
systematic review are drawn from the papers
included. These are referenced in the manuscript and
are accessible in the public repositories described in
the attached protocol.
Funding: This study was supported by a Wellcome
Trust Clinical PhD Fellowship Grant, awarded to Dr
Jamilah Meghji (106065/Z/14/A). The funders had no
role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
Conclusions
Post-TB structural lung pathology is common. Prospective data are required to determine
the evolution of this lung damage and its associated morbidity over time. Further data are
required from HIV-infected groups and those living in sSA.
Introduction
Chronic respiratory diseases (CRDs) are the fourth leading cause of non-communicable disease
(NCD) deaths globally, and pose a particular challenge to low and middle-income countries
(LMICs) where risk factors for respiratory damage including poverty-related in-utero and
early childhood exposures[1], exposure to acute respiratory infections[2], indoor biomass fuel
exposure[3, 4], a rising prevalence of smoking[5], chronic HIV-infection[6], and pulmonary
tuberculosis (PTB) intersect. A high prevalence of CRDs has been demonstrated in LMICs, and
these are expected to have a substantial impact on population health and health-services in the
coming years[7–10]. An improved understanding of the nature of CRDs in LMICs, their natu-
ral history, and associated morbidity and mortality is required if we are to design appropriate
prevention, diagnostic, and management strategies[11, 12].
Pulmonary TB remains an important cause of chronic respiratory impairment in LMICs.
5.2 million incident cases of PTB were reported globally in 2014[13], and the presence of long
term respiratory sequelae following PTB treatment is well established [14, 15]. Pulmonary
granuloma formation, tissue necrosis and liquefaction, and aberrant healing responses are
known features of TB disease[16, 17]. The persistence of abnormal airway physiology after
treatment has been documented in large population-based cross-sectional studies which show
1.37–2.94 higher odds of fixed airways obstruction in those with a history of PTB, compared to
those without[15, 18–21]. Previous TB has also been associated with chronic respiratory symp-
toms in LMICS: previous TB was the strongest predictor of chronic bronchitis within the 1996
South African Demographic & Health Survey [22] and the odds of a medical diagnosis of bron-
chiectasis were over 3-fold higher in those who had a history of TB, compared to those who
had not, in a population based study of 10,811 adults in China [23].
Whilst the evidence for abnormal spirometry and symptoms following PTB disease in
LMICS is clear, imaging of patients completing PTB treatment is not routinely performed, and
our understanding of the associated patterns of structural lung pathology remains limited.
Without these imaging data, we are not yet able to accurately phenotype patterns of post-TB
lung disease in to the meaningful categories required for clinical management, prognostication,
and ongoing research into the risk factors for post-TB lung damage [24, 25]. In addition, infor-
mation on the morbidity and mortality associated with post-TB lung damage remains limited,
but would be timely given the post-2015 TB agenda, which recognises the need for TB services
to mitigate the long-term detrimental impact of TB disease on patients’ lives and livelihoods
[26].
In this review we seek to improve our understanding of the nature and impact of post-TB
lung disease. We examine the literature on imaging defined structural post-TB lung damage,
and its relationship to patient-centred outcomes including functional impairment, respiratory
symptoms, and health-related quality of life. We have included studies using both plain chest
radiographs (CXR) and more detailed computerised tomography (CT) imaging in our review:
CXR is widely available for use in TB screening and diagnosis and may be of programmatic use
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in the diagnosis and management of post-TB lung damage, but CT provides a higher level of
detail and may provide more information on the true nature of this damage.
Methods
A protocol driven literature search was performed following PRISMA guidelines to identify
studies in which consecutive participants with pleural, miliary, or pulmonary TB were
recruited, where CXR or CT was performed after the completion of a full medical TB treatment
regimen, and where the prevalence of abnormal imaging or the severity of residual structural
lung damage was reported (S1 File). Cohort studies, cross-sectional studies and randomised
control trials (RCTs) were eligible for inclusion. There were no limits on publication date. Only
studies published in English were included.
Literature searches were conducted in Medline, Pubmed, Scopus, Web of Science, and the
Cochrane Library (July 2016) (Table 1). Reference lists from published reviews and reference
and citation lists of papers meeting inclusion criteria were reviewed to identify additional
articles.
The title and abstract of all identified studies were screened by two independent reviewers
(JM and HS). Full text review was performed on all selected articles. Studies restricted to paedi-
atric populations, in whom PTB has a varied presentation, or patients with non-HIV related
immunosuppression (chemotherapy, malignancy etc.) where imaging was likely to be affected
by comorbidities, were excluded. Data from the control arms of trials of adjuvant immuno-
modulatory therapies, in which patients received medical TB treatment only, were included.
A standardized data extraction form was used by 2 authors (JM and HS) to determine the
primary outcome of interest, which was the prevalence of abnormal imaging after TB treat-
ment. Information was collected on the patterns of imaging pathology, study characteristics,
participant characteristics, treatment regimens, and the modality and timing of thoracic imag-
ing. We recorded the proportion of studies that presented a measure of association between
imaging findings and other clinical parameters including spirometry, functional capacity,
respiratory symptoms, or health-related quality of life. Disagreements in study selection and
data extraction were resolved by discussion. Subgroup analyses were conducted to explore the
effect of different manifestations of disease (pleural vs. pulmonary), imaging modality (CXR
vs. CT), and multidrug-resistant (MDR) disease on the primary outcome. A narrative analysis
was conducted.
Study quality was determined using a modified version of the Newcastle-Ottowa score[27],
which included assessment of selection bias, adequacy of follow-up, the accuracy with which
baseline TB disease and treatment completion were determined, the quality and standardisation
of imaging interpretation, and the exclusion of those with structural lung disease preceding TB-
disease. A maximum score of 5 was possible for cohort studies, and 4 for cross-sectional studies
where no follow-up was required.
Table 1. Template for literature search: Pulmonary, pleural or military tuberculosis AND [CXR imaging
OR CT imaging].
Criteria Search terms
Pulmonary, pleural, or miliary
tuberculosis
“Tuberculosis, pulmonary”[Mesh] OR “tuberculosis, miliary[Mesh] OR
“tuberculosis, pleural”[Mesh] OR "pulmonary TB" OR "pulmonary
tuberculosis"
CXR Imaging “thoracic radiography"[MeSH] OR “chest x-ray" OR "chest radiograph" OR
"CXR"
CT imaging “computed tomography”[MeSH] OR "CT" OR "comput* tomography"
doi:10.1371/journal.pone.0161176.t001
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Results
We identified 10,740 articles, with 6909 articles remaining after removal of duplicates. Title
and abstract review identified 309 articles for full text review, of which 277 were excluded for
reasons including non-consecutive patient recruitment, imaging prior to treatment comple-
tion, and failure to report the absolute prevalence or severity of residual lung damage. Refer-
ence and citation searches identified 5 further articles for inclusion, giving a total of 37 articles
(Fig 1).
These papers covered the time period 1973–2015. They included 16 prospective cohort stud-
ies with patients recruited at TB diagnosis and imaged upon treatment completion, and one pro-
spective cohort study where imaging was performed 1 year post treatment completion[28].
There were 7 cross-sectional studies, 5 of which performed imaging at various time points after
treatment completion, and 7 retrospective cohort studies, which performed imaging upon treat-
ment completion. Data from 6 RCTs were included: data from both study arms were included
for two treatment regimen trials [29, 30] and a study investigating the effect of Vitamin-D and
L-arginine supplementation[31], but data from the control arms only were included from trials
investigating prednisolone use[32, 33], and a trial ofM. vaccae immunomodulation[34]. All
Fig 1. PRISMA flow chart.
doi:10.1371/journal.pone.0161176.g001
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RCTs performed imaging at treatment completion, and 1 also performed serial imaging
6-months later[32]. Only seven studies used CT imaging to describe structural pathology. Five
of these were conducted in the Americas, and all performed imaging at treatment completion.
Only one study of pleural disease used both CXR and CT imaging[32].
The total number of patients in all included studies was 4870, with disaggregated data avail-
able for 76 HIV-infected individuals. The median number of participants per study was 131
(range 13–1080). Studies were conducted in the Americas (n = 11), South East Asia (n = 9),
Europe (n = 6), the Western Pacific region (n = 6), and Africa (n = 2). Both of the studies con-
ducted in Africa were from South Africa and focused on either pleural[32] or MDR disease
[35]. 26 studies focused on PTB, 1 on the sequelae of miliary TB, 9 were restricted to pleural
TB, and 1 included patients with pulmonary, pleural or mediastinal TB[36]. The marked het-
erogeneity between studies made meta-analysis of their findings inappropriate.
Few studies specified the pattern of drug sensitivity (12/37), or previous episodes of TB
(10/37). Two studies of residual lung damage in patients receiving TB retreatment were
included, one of which was restricted to MDR patients[34, 37]. Two additional studies of
patients with MDR disease but unspecified histories of TB treatment were identified[35, 38].
The treatment regimens used varied widely; only 7 studies specified use of the gold standard
short-course treatment regimen, and only 2 out of 3 studies of MDR disease specified the use
of national treatment guidelines[35, 37].
Pulmonary disease
Of the 27 studies reporting the sequelae of pulmonary and miliary TB, prevalence estimates for
radiographic pathology were given in 17 CXR (Table 2) and 5 CT studies (Table 3), and varied
widely. Twelve CXR studies reported the prevalence of cavitation (8.3–83.7%), 3 reported
fibrosis (prevalence 25.0–70.4%) and 4 reported bronchiectasis (prevalence 4.3–11.2%). The
CT-based studies generally reported a lower prevalence of cavitation (7.4–34.6%), and a higher
prevalence of bronchiectasis (35.0–86.0%) and fibrosis (70.0–92.6%), than studies using CXR
imaging. A more diverse range of pathologies was noted on CT imaging: pleural thickening
was reported in 3 studies (prevalence 0.1–50.0%, n = 99), features potentially suggestive of
ongoing inflammation such as nodules were seen in all 5 studies (prevalence 25.9–55.8%,
n = 193), consolidation was reported in 4 studies (3.7–19.2%, n = 119), emphysema was seen
in in 2 studies (prevalence 15.4–45.0%, n = 72), and mosaicism was documented in 1 study
(prevalence 70%, n = 20). A broad range of severity scores were used to quantify residual dam-
age in 13 studies of PTB sequelae, only one of which was validated for scoring post-TB damage
rather than active PTB disease[39] (Table 4).
The prevalence of cavitation was higher in studies of re-treatment patients (68.8–83.7%),
and those treated for MDR disease (51.5–69.7%), compared to those with fully sensitive,
mixed, or unspecified sensitivities (8.3–49.7%). Only 1 study performed repeat imaging; this
demonstrated a reduction in the prevalence of cavitation during the 6-month follow-up period
from the end of TB treatment, but the findings were limited by a small sample size and 25%
loss to follow-up[34]
Pleural disease
The only radiological feature consistently reported in studies of pleural TB sequelae was the
presence of residual pleural thickening, but the thoracic area covered by this thickening was
not routinely reported. Residual thickening>10mm was seen in 19.6–46.0% of patients in 4
studies (n = 223) (Table 5). One study reported both CXR and CT findings following pleural
Residual Structural Lung Pathology following TB Disease
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TB, with mild pleural thickening>2mm seen in 50.0% (18/36) on CXR, and 60.0% (21/35) on
CT[32].
Relationship of imaging changes and other respiratory parameters
Although several studies described spirometry following PTB disease, only 2 studies directly
related physiological impairment to imaging findings. The first showed a statistically signifi-
cant inverse correlation between both FEV1 (forced expiratory flow in 1-second) and FVC
(forced vital capacity), and the extent of radiographic abnormality on CXR in 127 adults who
were a median of 11 months (IQR 6–18 months) post completion of TB treatment[39]. The
second described imaging findings in patients with (n = 24) and without (n = 46) fixed airway
obstruction on spirometry following treatment completion. Those with airway obstruction had
had more previous episodes of TB (1.9+/-0.7 vs. 1.4+/-0.6, p = 0.009), but had more fibrocavi-
tatory changes evident on CXR imaging[59].
The only study to relate imaging findings to functional capacity included 18 patients com-
pleting treatment for MDR-TB, and found a higher level of impairment amongst those with
more marked radiographic damage: 64% of those with Grade I damage (7/11) failed to reach
an expected 6-minute walking distance, compared to 100% of patients with Grade III damage
(3/3). However, the findings of this study were limited by a small sample size and a lack of sta-
tistical testing[37]. Only one study described the relationship between imaging findings and
patient quality of life. This was a cross-sectional study of 198 patients who had been treated for
TB a mean of 16.5 years previously, and found no statistically significant difference in the
symptoms, activity, impact, or overall St George’s Respiratory Questionnaire scores between
those with pathology affecting2 vs.>2 CXR zones[47].
Table 3. Studies reporting prevalence of imaging patterns on CT imaging on completion of treatment for pulmonary tuberculosis.
Author,
Year
Country Study
design
Participant
HIV status
Treatment
episode
Drug
sensitivity
Number of
participants
Prevalence of pathology (%) Quality
score
Poey, 1997
[49]
Martinique Prospective
cohort
Negative Not
speciﬁed
Not
speciﬁed
27 Cavitation: 7.4%, Bronchiectasis:
85.2%, Fibrosis: 92.6%, Pleural
thickening: 4.8%, Nodules: 25.9%,
Consolidation: 3.7%, Ground glass
pattern: 7.4%, Reticulation: 44.4%,
3/5
Long, 1998
[50]
Canada Prospective
cohort
Negative Not
speciﬁed
Fully
sensitive
20 Bronchiectasis: 50.0%, Fibrosis:
80.0%, Pleural thickening: 0.1%,
Nodules: 55.0%, Consolidation:
15.0%, Emphysema/Bullae: 45.0%,
Mosaicism: 70.0%
3/5
Bombarda,
2003 [51]
Brazil Prospective
cohort
Negative Not
speciﬁed
Not
speciﬁed
20 Cavitation: 30.0%, Bronchiectasis:
35.0%, Fibrotic bands: 70.0%,
Nodules: 55.0%, Consolidation:
15.0%, Mass lesions: 45%
3/5
Lee, 2008
[52]
Taiwan Prospective
cohort
Negative First episode Fully
sensitive
52 Cavitation: 34.6%, Bronchiectasis:
44.2%, Fibrosis: 92.3%, Pleural
thickening: 50.0%, Nodules: 55.8%,
Consolidation: 19.2%, Emphysema/
Bullae: 15.4%, Mass lesions: 7.7%,
Ground glass pattern: 1.9%,
Parenchymal calciﬁcation: 11.5%
1/5
Ruﬁno, 2015
[53]
Brazil Prospective
cohort
Not speciﬁed Not
speciﬁed
Not
speciﬁed
74 Cavitation: 16%, Bronchiectasis: 86%,
Nodules: 48%, Parenchymal opacities:
25%, Parenchymal calciﬁcations: 47%,
Architectural distortion: 91%
1/5
doi:10.1371/journal.pone.0161176.t003
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Discussion
This review suggests a high prevalence of residual structural lung pathology following PTB
treatment, and highlights the contribution that CT imaging may make to our understanding of
this pathology. Several gaps in the literature have been identified, including a paucity of pro-
spective data on the evolution of post-TB lung damage over time, limited geographical cover-
age of studies, little data from HIV-infected adults, and little information on the relationship
between structural pathology, physiological abnormalities, and patient centered outcomes.
Despite the increasing focus on long-term patient outcomes within the post-2015 TB
agenda, international targets for the management of PTB disease remain microbiologically and
mortality driven: standard short course treatment for fully sensitive disease is provided for
6-months with discharge from health services on completion and no routine follow-up thereaf-
ter. Thoracic imaging is not routinely performed at the conclusion of treatment, and national
TB treatment programmes are required to report data on treatment completion and survival
only. Our review describes a high prevalence of residual abnormalities on imaging following
medical treatment for PTB, in keeping with existing evidence on the high burden of abnormal
airway physiology following PTB[15, 21]. This is particularly high amongst patients treated for
MDR disease, which is of concern given the increasing prevalence of drug resistance in many
high TB prevalence settings[67]. Our review suggests that there may be a substantial burden of
undetected lung damage amongst patients completing TB treatment, but that our understand-
ing of the combined structural/physiological nature of this damage, and the consequences of
Table 5. Studies of residual pleural thickening (RPT) on completion of treatment for TB pleural
effusion.
Imaging
modality
Author,
Year
Country Study design Number of
participants
Participant
HIV status
Prevalence of
pathology (%)
Quality
score
CXR Kunter,
2002[60]
Turkey Retrospective
cohort
47 Not
speciﬁed
RPT>2mm:
63.8%
RPT>10mm:
25.5%
2/5
CXR Uskal,
2005[61]
Turkey Retrospective
cohort
121 Not
speciﬁed
RPT>2mm:
52.1%
3/5
CXR Wong,
2005[62]
Hong
Kong
Retrospective
cohort
70 Not
speciﬁed
RPT>10mm:
41.4%
2/5
CXR Barbas,
1991[63]
Brazil Prospective
cohort
44 Not
speciﬁed
RPT>2mm:
52.3%
2/5
CXR de Pablo,
1997 [64]
Spain Prospective
cohort
56 Mixed RPT>2mm:
42.9%
RPT>10mm:
19.6%
3/5
CXR Frye, 1997
[65]
America Retrospective
cohort
20 Positive Any RPT:
65.0%
3/5
CXR Galarza,
1995 [33]
Spain RCT—steroid
use*
60 Negative Any RPT:
8.3%
2/5
CXR Wyser,
1996 [32]
South
Africa
RCT—steroid
use*
36 Negative RPT>2mm:
50.0%
4/5
CT Wyser,
1996 [32]
South
Africa
RCT—steroid
use*
35 Negative RPT>2mm:
60.0%
4/5
CT Seiscento,
2007 [66]
Brazil Prospective
cohort
50 Not
speciﬁed
RPT>10mm:
46.0%
3/5
*Date from study arm including steroids excluded
doi:10.1371/journal.pone.0161176.t005
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this for patients is limited. There remains insufficient evidence on which to base any changes
to imaging and follow-up practices within existing TB programs.
Our review demonstrates differences in the prevalence and patterns of lung damage detected
using CXR and CT imaging. CXR studies focused on cavitation, bronchiectasis, and fibrosis,
and reported cavitation as the most common finding. In CT studies the prevalence of bronchiec-
tasis was higher than that of cavitation, with possible features of ongoing inflammation (nodules
and consolidation), emphysema, and mosaicism which may reflect small airways disease also
reported. Whilst access to CT imaging is unlikely to be available in LMICs for routine assess-
ment of patients after PTB treatment, limited use within research studies may have a role in
accurately phenotyping disease, and identifying pathologies that could otherwise be missed.
Studies performing paired CXR and CT imaging after pulmonary TB will then be required to
determine the sensitivity of CXR imaging used within National Treatment Programs in LMICS
for this CT defined structural damage.
Efforts to better define post-TB lung pathology will need to include an understanding of its
evolution over time if we are to improve long-term patient outcomes. We identified a paucity
of prospective data on the trajectory of imaging defined post-TB lung disease. This limitation is
also seen in our understanding of the evolution of lung function following PTB, which is based
on cross-sectional studies[68]. Uncertainty therefore remains about the rate and drivers of
recovery/deterioration in those with post-TB lung damage. Factors influencing the progression
of lung damage may include modifiable exposures such as smoking, biomass fuel[69, 70], and
ongoing respiratory tract infections[71]. Further research in this area may inform strategies to
prevent decline in this group.
Few studies attempted to examine the relationship between lung damage and patient func-
tional capacity, symptom burden, and quality of life. The available data suggest that exercise
capacity may decrease with increasing extents of structural pathology, but sample sizes in the
one study to assess this were low[37]. The only study relating structural pathology to quality of
life was vulnerable to selection bias, and the nature of this relationship therefore remains
unclear[47]. A cohort study of patients with extensively destroyed lung after TB disease has
confirmed a high incidence of infective exacerbations and mortality in this group[72], but fur-
ther prospective data are required on outcomes amongst those with residual respiratory dam-
age of a broader range of patterns and severity, from the time of treatment.
We identified a paucity of data from sSA and from HIV-positive patients. Given the conver-
gence of a high TB prevalence and multiple risk factors for disease progression in sSA, data
from this region is critical to our understanding of the public health impact of residual lung
damage following TB treatment. HIV-positive individuals have a higher risk of developing TB
disease, so should also be a focus of research. Although this group have atypical PTB presenta-
tions, with less structural damage seen at diagnosis[73], they may experience a differential pat-
tern of progression of lung disease during or after treatment due to the effects of opportunistic
infections, immune reconstitution syndrome and HIV-related immune activation on the lung
[67, 74–76]. HIV-positive patients may also be particularly vulnerable to decreased quality of
life and impaired functional capacity related to residual damage, and further analysis of respi-
ratory outcomes in this group is urgently required[77].
The quality of studies identified in this review varied substantially. None included imaging
prior to TB diagnosis, thus the presence of structural damage present prior to TB disease was
not truly excluded. The majority of studies failed to specify how the radiological abnormalities
reported on imaging were defined, and did not use gold-standard methods of reporting, mak-
ing them vulnerable to misclassification of outcomes. Selection bias was a common issue; many
studies were unclear about the reference population from which participants were drawn. The
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cross-sectional studies imaging patients sometime after treatment completion consistently
struggled to locate eligible patients, and were limited by survival bias.
The strengths of our review include the use of several databases with no limitation on study
dates, and the use of reference and citation review to identify additional papers. The study is
limited by the inclusion of English language articles only. The heterogeneity of patient popula-
tions, treatment regimens, and the timing and modality of imaging meant that we were unable
to perform a meta-analysis.
Conclusion
This systematic review identified a high burden of structural pathology after PTB treatment. A
better understanding of the nature of this pathology, evolution of disease over time, factors
driving deterioration, and the impact of respiratory pathology on patients’ lives and livelihoods
is needed to guide clinical management and health-service planning. Data on the sensitivity of
CXR and spirometric indices for structural changes seen on CT imaging are required, together
with studies examining post-TB lung damage in HIV-infected individuals and those from sSA.
Further investigation of these areas is required if we are to meet the post-2015 TB aim of reduc-
ing the long-term detrimental impact of TB disease on patients’ lives and livelihoods.
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